Nathan Dyjack1, Elena Goleva2, Cydney Rios1, Byung Eui Kim2, Lianghua Bin2, Patricia Taylor2, Caroline Bronchick2, Clifton F Hall2, Brittany N Richers2, Max A Seibold3, Donald Y M Leung4. 1. Center for Genes, Environment, and Health, National Jewish Health, Denver, Colo. 2. Department of Pediatrics, National Jewish Health, Denver, Colo. 3. Center for Genes, Environment, and Health, National Jewish Health, Denver, Colo; Department of Pediatrics, National Jewish Health, Denver, Colo; Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver, Aurora, Colo. Electronic address: seiboldm@njhealth.org. 4. Department of Pediatrics, National Jewish Health, Denver, Colo; Department of Pediatrics, University of Colorado Denver, Aurora, Colo. Electronic address: Leungd@NJHealth.org.
Abstract
BACKGROUND: Expression profiling of skin biopsy specimens has established molecular features of the skin in patients with atopic dermatitis (AD). The invasiveness of biopsies has prevented their use in defining individual-level AD pathobiological mechanisms (endotypes) in large research studies. OBJECTIVE: We sought to determine whether minimally invasive skin tape strip transcriptome analysis identifies gene expression dysregulation in AD and molecular disease endotypes. METHODS: We sampled nonlesional and lesional skin tape strips and biopsy specimens from white adult patients with AD (18 male and 12 female patients; age [mean ± SE], 36.3 ± 2.2 years) and healthy control subjects (9 male and 16 female subjects; age [mean ± SE], 34.8 ± 2.2 years). AmpliSeq whole-transcriptome sequencing was performed on extracted RNA. Differential expression, clustering/pathway analyses, immunostaining of skin biopsy specimens, and clinical trait correlations were performed. RESULTS: Skin tape expression profiles were distinct from skin biopsy profiles and better sampled epidermal differentiation complex genes. Skin tape expression of 29 immune and epidermis-related genes (false discovery rate < 5%) separated patients with AD from healthy subjects. Agnostic gene set analyses and clustering revealed 50% of patients with AD exhibited a type 2 inflammatory signature (type 2-high endotype) characterized by differential expression of 656 genes, including overexpression of IL13, IL4R, CCL22, CCR4 (log2 fold change = 5.5, 2.0, 4.0, and 4.1, respectively) and at a pathway level by TH2/dendritic cell activation. Both expression and immunostaining of skin biopsy specimens indicated this type 2-high group was enriched for inflammatory, type 2-skewed dendritic cells expressing FcεRI. The type 2-high endotype group exhibited more severe disease by using both the Eczema Area and Severity Index score and body surface area covered by lesions. CONCLUSION: Minimally invasive expression profiling of nonlesional skin reveals stratification in AD molecular pathology by type 2 inflammation that correlates with disease severity.
BACKGROUND: Expression profiling of skin biopsy specimens has established molecular features of the skin in patients with atopic dermatitis (AD). The invasiveness of biopsies has prevented their use in defining individual-level AD pathobiological mechanisms (endotypes) in large research studies. OBJECTIVE: We sought to determine whether minimally invasive skin tape strip transcriptome analysis identifies gene expression dysregulation in AD and molecular disease endotypes. METHODS: We sampled nonlesional and lesional skin tape strips and biopsy specimens from white adult patients with AD (18 male and 12 female patients; age [mean ± SE], 36.3 ± 2.2 years) and healthy control subjects (9 male and 16 female subjects; age [mean ± SE], 34.8 ± 2.2 years). AmpliSeq whole-transcriptome sequencing was performed on extracted RNA. Differential expression, clustering/pathway analyses, immunostaining of skin biopsy specimens, and clinical trait correlations were performed. RESULTS: Skin tape expression profiles were distinct from skin biopsy profiles and better sampled epidermal differentiation complex genes. Skin tape expression of 29 immune and epidermis-related genes (false discovery rate < 5%) separated patients with AD from healthy subjects. Agnostic gene set analyses and clustering revealed 50% of patients with AD exhibited a type 2 inflammatory signature (type 2-high endotype) characterized by differential expression of 656 genes, including overexpression of IL13, IL4R, CCL22, CCR4 (log2 fold change = 5.5, 2.0, 4.0, and 4.1, respectively) and at a pathway level by TH2/dendritic cell activation. Both expression and immunostaining of skin biopsy specimens indicated this type 2-high group was enriched for inflammatory, type 2-skewed dendritic cells expressing FcεRI. The type 2-high endotype group exhibited more severe disease by using both the Eczema Area and Severity Index score and body surface area covered by lesions. CONCLUSION: Minimally invasive expression profiling of nonlesional skin reveals stratification in AD molecular pathology by type 2 inflammation that correlates with disease severity.
Authors: Prescott G Woodruff; Barmak Modrek; David F Choy; Guiquan Jia; Alexander R Abbas; Almut Ellwanger; Laura L Koth; Joseph R Arron; John V Fahy Journal: Am J Respir Crit Care Med Date: 2009-05-29 Impact factor: 21.405
Authors: Susan D Reynolds; Cydney Rios; Agata Wesolowska-Andersen; Yongbin Zhuang; Mary Pinter; Carrie Happoldt; Cynthia L Hill; Scott W Lallier; Gregory P Cosgrove; George M Solomon; David P Nichols; Max A Seibold Journal: Am J Respir Cell Mol Biol Date: 2016-09 Impact factor: 6.914
Authors: Pei-Song Gao; Nicholas M Rafaels; Tracey Hand; Tanda Murray; Mark Boguniewicz; Tissa Hata; Lynda Schneider; Jon M Hanifin; Richard L Gallo; Li Gao; Terri H Beaty; Lisa A Beck; Kathleen C Barnes; Donald Y M Leung Journal: J Allergy Clin Immunol Date: 2009-09 Impact factor: 10.793
Authors: Weijun Luo; Michael S Friedman; Kerby Shedden; Kurt D Hankenson; Peter J Woolf Journal: BMC Bioinformatics Date: 2009-05-27 Impact factor: 3.169
Authors: Jonathan A Cohen; Tara N Edwards; Andrew W Liu; Toshiro Hirai; Marsha Ritter Jones; Jianing Wu; Yao Li; Shiqun Zhang; Jonhan Ho; Brian M Davis; Kathryn M Albers; Daniel H Kaplan Journal: Cell Date: 2019-07-25 Impact factor: 41.582
Authors: Wendy F Davidson; Donald Y M Leung; Lisa A Beck; Cecilia M Berin; Mark Boguniewicz; William W Busse; Talal A Chatila; Raif S Geha; James E Gern; Emma Guttman-Yassky; Alan D Irvine; Brian S Kim; Heidi H Kong; Gideon Lack; Kari C Nadeau; Julie Schwaninger; Angela Simpson; Eric L Simpson; Jonathan M Spergel; Alkis Togias; Ulrich Wahn; Robert A Wood; Judith A Woodfolk; Steven F Ziegler; Marshall Plaut Journal: J Allergy Clin Immunol Date: 2019-01-09 Impact factor: 10.793
Authors: Byung Eui Kim; Elena Goleva; Peter S Kim; Kathryn Norquest; Caroline Bronchick; Patricia Taylor; Donald Y M Leung Journal: J Invest Dermatol Date: 2019-06-06 Impact factor: 8.551
Authors: Nichole Reisdorph; Michael Armstrong; Roger Powell; Kevin Quinn; Kevin Legg; Donald Leung; Rick Reisdorph Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2018-03-21 Impact factor: 3.205
Authors: Donald Y M Leung; Agustin Calatroni; Livia S Zaramela; Petra K LeBeau; Nathan Dyjack; Kanwaljit Brar; Gloria David; Keli Johnson; Susan Leung; Marco Ramirez-Gama; Bo Liang; Cydney Rios; Michael T Montgomery; Brittany N Richers; Clifton F Hall; Kathryn A Norquest; John Jung; Irina Bronova; Simion Kreimer; C Conover Talbot; Debra Crumrine; Robert N Cole; Peter Elias; Karsten Zengler; Max A Seibold; Evgeny Berdyshev; Elena Goleva Journal: Sci Transl Med Date: 2019-02-20 Impact factor: 17.956
Authors: Elizabeth Huiwen Tham; Nathan Dyjack; Byung Eui Kim; Cydney Rios; Max A Seibold; Donald Y M Leung; Elena Goleva Journal: J Allergy Clin Immunol Date: 2018-11-14 Impact factor: 10.793